Article thumbnail

The secretory phospholipase A2 group IIA: a missing link between inflammation, activated renin-angiotensin system, and atherogenesis?

By Dimitar Divchev and Bernhard Schieffer


Inflammation, lipid peroxidation and chronic activation of the rennin – angiotensin system (RAS) are hallmarks of the development of atherosclerosis. Recent studies have suggested the involvement of the pro-inflammatory secretory phospholipase A2 (sPLA2)-IIA in atherogenesis. This enzyme is produced by different cell types through stimulation by pro-inflammatory cytokines. It is detectable in the intima and in media smooth muscle cells, not only in atherosclerotic lesions but also in the very early stages of atherogenesis. sPLA2-IIA can hydrolyse the phospholipid monolayers of low density lipoproteins (LDL). Such modified LDL show increased affinity to proteoglycans. The modified particles have a greater tendency to aggregate and an enhanced ability to insert cholesterol into cells. This modification may promote macrophage LDL uptake leading to the formation of foam cells. Furthermore, sPLA2-IIA is not only a mediator for localized inflammation but may be also used as an independent predictor of adverse outcomes in patients with stable coronary artery disease or acute coronary syndromes. An interaction between activated RAS and phospholipases has been indicated by observations showing that inhibitors of sPLA2 decrease angiotensin (Ang) II-induced macrophage lipid peroxidation. Meanwhile, various interactions between Ang II and oxLDL have been demonstrated suggesting a central role of sPLA2-IIA in these processes and offering a possible target for treatment. The role of sPLA2-IIA in the perpetuation of atherosclerosis appears to be the missing link between inflammation, activated RAS and lipidperoxidation

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1995). An essential role for lysophosphatidylcholine in the inhibition of platelet aggregation by secretory phospholipase A2.
  2. (1989). and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat mesangial cells. Biochem Biophys Res Commun,159:385–94.
  3. (1999). Ang-II atherogenicity in E0 mice is associated with increased cellular cholesterol biosynthesis.
  4. (1995). Ang-II stimulates macrophagemediated oxidation of LDL.
  5. (2001). Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL: a possible role for interleukin-6. Arterioscler Thromb Vasc Biol,
  6. (2006). Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A(2)-dependent lipid peroxidation.
  7. (1998). Angiotensin, LDL peroxidation and Atherosclerosis. Life Sciences,
  8. (1993). Antisense inhibition of group II phospholipase A2 expression blocks the production of prostaglandin E2 by P388Dresden cells.
  9. (2005). Associations of plasma C-reactive protein levels with the presence and extent of coronary stenosis in patients with stable coronary artery disease; Atherosclerosis,
  10. (1999). Atherosclerosis – an infl ammatory disease.
  11. (2002). Biological effects of secretory phospholipase A(2) group IIA on lipoproteins and in atherogenesis.
  12. (2007). Bone marrow transplantation reveals that recipient AT1a receptors are required to initiate Angiotensin II–induced atherosclerosis and aneurysms. Arterioscler Thromb Vasc Biol,
  13. (1999). Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease.
  14. (1991). Circulating phospholipase A2 activity associated with sepsis and septic shock is indistinguishable from that associated with rheumatoid arthritis. Infl ammation,
  15. (2007). Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: The EPIC-NORFOLK Study. Arterioscler Thromb Vasc Biol,
  16. (2005). Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes.
  17. (2002). Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (55 years) men and women.
  18. (1988). Enzymatic modifi cation of low density lipoprotein by purifi ed lipoxygenase plus phospholipase A2 mimics cell-mediated oxidative modifi cation.
  19. (1994). Evidence that secretory phospholipase A2 plays a role in arachidonic acid release and eicosanoid biosynthesis by mast cells.
  20. (2000). Exogenously added human group X secreted phospholipase A2 but not the group IB, IIA, and V enzymes effi ciently release arachidonic acid from adherent mammalian cells.
  21. (2000). Expression of human secretory group IIA phospholipase A2 is associated with reduced concentrations of plasma cholesterol in transgenic mice. Infl ammation,
  22. (2000). Expression of secretory group IIA phospholipase A(2) in relation to the presence of microbial agents, macrophage infi ltrates, and transcripts of proinfl ammatory cytokines in human aortic tissues. Arterioscler Thromb Vasc Biol,
  23. (1995). Expression of type-II phospholipase A2 in alveolar macrophages: down-regulation by an infl ammatory signal.
  24. (2001). Facilitative interaction between angiotensin II and oxidized LDL in cultured human coronary artery endothelial cells. J Renin Angiotensin Aldosterone Syst,
  25. (1998). Generation of lyso-phospholipids from surfactant in acute lung injury is mediated by type-II phospholipase A2 and inhibited by a direct surfactant protein A-phospholipase A2 protein interaction.
  26. (1990). Glucocorticoids suppress group II phospholipase A2 production by blocking mRNA synthesis and posttranscriptional expression.
  27. (2004). Group V sPLA2 hydrolysis of LDL results in spontaneous particle aggregation and promotes macrophage foam cell formation. Arterioscler Thromb Vasc Biol,
  28. (2000). HDL modifi cation by secretory phospholipase A2 promotes scavenger receptor class B type I interaction and accelerates HDL catabolism.
  29. (1997). High specifi city of human secretory class II phospholipase A2 for phosphatidic acid.
  30. (2002). Identifi cation, regulation and function of a novel lectin like oxidized low density lipoprotein receptor.
  31. (1998). Impact of major cardiovascular disease risk factors, particularly in combination, on 22-year mortality in women and men.
  32. (1993). Increased synthesis and secretion of a 14-kDa phospholipase A2 by guinea pig alveolar macrophages: dissociation from arachidonic acid liberation and modulation by dexamethasone.
  33. (1998). Induction of cyclooxygenase2 by secretory phospholipases A2 in nerve growth factor-stimulated rat serosal mast cells is facilitated by interaction with fi broblasts and mediated by a mechanism independent of their enzymatic functions.
  34. (1993). Induction of group II phospholipase A2 expression and pathogenesis of the sepsis syndrome. Circ Shock,
  35. (1991). Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acutephase response.
  36. (1997). Infl ammatory activation of arachidonic acid signaling in murine P388D1 macrophages via sphingomyelin synthesis.
  37. (2000). Interferon-g induces secretory group IIA phospholipase A2 in human arterial smooth muscle cells: involvement of cell differentiation, STAT-3 activation, and modulation by other cytokines.
  38. (1991). Interleukin 1β, tumor necrosis factor and forskolin stimulate the synthesis and secretion of group II phospholipase A2 in rat mesangial cells.
  39. (1991). Intracellular localization of group II phospholipase A2 in rat vascular smooth muscle cells and its possible relationship to eicosanoid formation.
  40. (2001). Lipolysis of LDL by human secretory phospholipase A2 induces particle fusion and enhances the retention of LDL to human aortic proteoglycans. Arterioscler Thromb Vasc Biol,
  41. (2000). Losartan Inhibits Cellular Uptake of Oxidized LDL by Monocyte-Macrophages from Hypercholesterolemic Patients.
  42. (2005). Macrophage-specifi c expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress.
  43. (1997). Minimal oxidation and storage of low density lipoproteins result in an increased susceptibility to phospholipid hydrolysis by phospholipase A2. Atherosclerosis,
  44. (2000). Molecular basis for the association of group IIA phospholipase A2 and decorin in human atherosclerotic lesions. Circ Res,
  45. (1999). Molecular cloning of two new human paralogs of 85-kDa cytosolic phospholipase A2.
  46. (1993). Molecular nature of phospholipase A2 involved in prostaglandin I2 synthesis in human umbilical vein endothelial cells: possible participation of cytosolic and extracellular type II phospholipase A2.
  47. (2003). New phospholipase A2 isozymes with a potential role in atherosclerosis. Curr Opin Lipidol,
  48. (1996). Novel group V phospholipase A2 involved in arachidonic acid mobilization in murine P388D1 macrophages.
  49. (1999). On the diversity of secreted phospholipases A(2). Cloning, tissue distribution, and functional expression of two novel mouse group II enzymes.
  50. (2000). Overexpression of Secretory Phospholipase A2 causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I*.
  51. (1991). Phagocytosis of lipaseaggregated low density lipoprotein promotes macrophage foam cell formation. Sequential morphological and biochemical events. Arterioscler Thromb,
  52. (1998). Phospholipase A2 type II binds to extracellular matrix biglycan: modulation of its activity on LDL by colocalization in glycosaminoglycan matrixes. Arteioscler Thromb Vasc Biol,
  53. (1992). Phospholipase A2-modifi ed LDL is taken up at enhanced rate by macrophages.
  54. (2002). Potent modifi cation of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation.
  55. (2002). Presence of the M-type sPLA2 receptor on neutrophils and its role in elastase release and adhesion.
  56. (2003). Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention.
  57. (2000). Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris.
  58. (1997). Properties and regulation of cytosolic phospholipase A2.
  59. (1997). Prostaglandin synthase-1 and prostaglandin synthase-2 are coupled to distinct phospholipases for the generation of prostaglandin D2 in activated mast cells. J Biol Chem,
  60. (1999). Protection by group II phospholipase A2 against Staphylococcus aureus.
  61. (1988). Purifi cation and characterization of membrane-bound phospholipase A2 from rat platelets.
  62. (1990). Purifi cation of a cellular (granulocyte) and an extracellular (serum) phospholipase A2 that participate in the destruction of Escherichia coli in a rabbit infl ammatory exudate.
  63. (1998). Regulation of secretory type-II phospholipase A2 and of lysophosphatidic acid synthesis. Adv Enzyme Regul,
  64. (2000). Regulation of the angiotensin AT1 receptor by hypercholesterolaemia. Diabetes Obes Metab,
  65. (1998). Regulation of the cellular expression of secretory and cytosolic phospholipases A2, and cyclooxygenase-2 by peptide growth factors. Biochim Biophys Acta,
  66. (1999). Role of group II secretory phopholipase A2 in atherosclerosis: 2. Potential involvment of biologically active oxidized phospholipids. Arterioscler Thromb Vasc Biol,
  67. (1999). Role of group II secretory phospholipase A2 in atherosclerosis. 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIA phospholipase A2. Arterioscler Thromb Vasc Biol,
  68. (2002). Role of group IIA and group V secretory phospholipases A2 in the metabolism of lipoproteins. Substrate specifi cities of the enzymes and the regulation of their activities by sphingomyelin.
  69. (2000). Secretory group II phospholipase A2; a newly recognized acute-phase reactant with a role in atherogenesis. Circ Res,
  70. (1999). Secretory low-molecular-weight phospholipases A2 and their specifi c receptor in bile ducts of patients with intrahepatic calculi: factors of chronic proliferative cholangitis.
  71. (1997). Secretory non-pancreatic phospholipase A2: infl uence on lipoprotein metabolism.
  72. (1998). Secretory phospholipase A2 activates the cascade of mitogen-activated protein kinases and cytosolic phospholipase A2 in the human astrocytoma cell line 1321N1.
  73. (2005). Secretory phospholipase A2 enzymes in atherogenesis.
  74. (2006). Secretory phospholipase A2 of group IIA: Is it an offensive or a defensive player during atherosclerosis and other infl ammatory diseases? Prostaglandins Other Lipid Mediat,
  75. (2004). Secretory phospholipase A2 type IIA and V in atherosclerosis: expression by vascular cells, localization in lesions and hydrolysis of lipoproteins. Atherosclerosis Suppl,
  76. (2003). Secretory phospholipases A2 as multivalent mediators of infl ammatory and allergic disorders. Int Arch Allergy Immunol,
  77. (1992). Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall fi ndings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med,
  78. (2005). Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women The EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol,
  79. (2000). Specifi c physiological roles of cytosolic phospholipase A(2) as defi ned by gene knockouts.
  80. (1999). The 85-kD cytosolic phospholipase A2 knockout mouse: a new tool for physiology and cell biology.
  81. (1997). The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-defi cient mice.
  82. (2005). The catalytically active secretory phospholipase A2 type IIA is involved in restenosis development after PTCA in human coronary arteries and generation of atherogenic LDL.
  83. (2000). The expanding superfamily of phospholipase A2 enzymes: classifi cation and characterization. Biochim Biophys Acta,
  84. (1996). Transcellular prostaglandin production following mast cell activation is mediated by proximal secretory phospholipase A2 and distal prostaglandin synthase 1.
  85. (2002). Transcriptional regulation of the rat type IIA phospholipase A2 gene by cAMP and interleukin-1b in vascular smooth muscle cells: interplay of the CCAAT/enhancer binding protein (C/EBP), nuclear factor-kB and Ets transcription factors.
  86. (2003). Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes? Cardiovasc Res,

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.